No Data
Watson Biotech: 2024 Annual Results Forecast
Walvax Biotechnology (300142.SZ): Expected net income for the year 2024 is between 0.14 billion yuan and -0.18 billion yuan.
Gelonghui, January 20th丨Walvax Biotechnology (300142.SZ) announced its earnings forecast for 2024. The net income attributable to shareholders of the listed company is expected to be 0.14 billion yuan to 0.18 billion yuan, which represents a year-on-year decline of 57% to 67%; the net income after deducting non-recurring gains and losses is expected to be 0.11 billion yuan to 0.15 billion yuan, a year-on-year decrease of 74% to 81%; revenue is approximately 2.86 billion yuan. During the reporting period, the company's 13-valent pneumococcal polysaccharide conjugate vaccine maintained the largest market share domestically; however, it was impacted by a decline in the number of newborns and increased market competition.
Walvax Biotechnology (300142.SZ): The mRNA vaccine products under development primarily focus on preventing infectious diseases.
On December 26th, Gelonghui reported that Walvax Biotechnology (300142.SZ) recently stated during an investor relations activity that the current main research areas of mRNA vaccine development are infectious diseases and cancer, and that it is beginning to explore the shift from preventive products to therapeutic products. Since its establishment, the company has remained focused on the research and production of innovative blockbuster vaccines, with its mRNA vaccine products primarily aimed at preventing infectious diseases. The company will closely monitor the application of new technologies in innovative fields like cancer and the development of related products.
Walvax Biotechnology (300142.SZ): Currently engaged in the clinical development plan for the 9-valent HPV vaccine product, maintaining close communication with the CDE.
On December 26, Gelonghui reported that Walvax Biotechnology (300142.SZ) recently stated in an investor relations activity that the work for its subsidiary in Shanghai, Ze Run, for the phase III clinical study of the 9-valent HPV vaccine is progressing continuously. Currently, the phase III clinical trial comparing the immunogenicity of this vaccine with similar vaccines is in the data statistics analysis and clinical research report writing phase. The company is actively maintaining close communication with CDE, striving to promote the clinical research of protective efficacy with the optimal strategy based on the clinical development plan for the 9-valent HPV vaccine product.
Walvax Biotechnology (SZSE:300142) Investors Are Sitting on a Loss of 78% If They Invested Three Years Ago
Walvax Biotechnology Gets China Clinical Trial Approval for Anti-Tetanus Shot
There's Reason For Concern Over Walvax Biotechnology Co., Ltd.'s (SZSE:300142) Price
No Data
